Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain

Expert Opinion on Investigational Drugs

Volumn 17, Issue 1, 2008, Pages 85-95

  Davis, Mellar P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Nabilone; Nausea; Pain; Vomiting

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APOMORPHINE; BENZODIAZEPINE DERIVATIVE; CANNABIDIOL; CANNABINOID; CANNABINOL; CHLORPROMAZINE; CISPLATIN; DEXAMETHASONE; DOMPERIDONE; DOXORUBICIN; DRONABINOL; HALOPERIDOL; INDOMETACIN; LEVONANTRADOL; METOCLOPRAMIDE; NABILONE; NEUROLEPTIC AGENT; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OPIATE; PLACEBO; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; TETRAHYDROCANNABINOL; THIETHYLPERAZINE; UNINDEXED DRUG; ANALGESIC AGENT; DRUG DERIVATIVE;

ANALGESIA; ANTICONVULSANT ACTIVITY; ANTIEMETIC ACTIVITY; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COORDINATION DISORDER; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPHORIA; EUPHORIA; HALLUCINATION; HUMAN; HYPERTENSION; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PARANOIA; PHARMACODYNAMICS; PHARMACOGENETICS; PSYCHOSIS; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; VERTIGO; CHEMICALLY INDUCED DISORDER; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NAUSEA; PAIN; TETRAHYDROCANNABINOL; TREATMENT OUTCOME; VOMITING;

EID: 38949192062     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.1.85     Document Type: Article

References (124)

1. Mechoulam R, Hanu L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 2001;6(2):67-73
2. Mechoulam R, Hanu L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 2000;108(1-2):1-13
3. Ward A, Holmes B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1985;30(2):127-44
4. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006;147(Suppl 1):S163-SI71
5. Howlett AC. Inhibition of neuroblastoma. adehylate cyclase by cannabinoid and nantradol compounds. Life Sci 1984;35(17):1803-10
6. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;38(2):151-78
7. Herkenham. M. Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Res Monogr 1991;112:129-45
8. Howlett AC, Breivogel CS, Childers SR, et al. Carinabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47(Supp 1):345-58
9. Martin BR, Compton DR, Thomas BF, et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 1991;40(3):471-8
10. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999;58(4):315-48
11. Freedland CS, Whitlow CT, Smith HR, et al. Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and tolerant animals: a quantitative 2-[14C]deoxyglucose study. Brain Res 2003;962(1-2):169-79
12. Fernandez JR, Allison DB. Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs 2004;5(4):430-5
13. Behbehani MM. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 1995;46(6):575-605
14. Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 1998;242(1):33-6
15. Lichtman AH, Martin BR. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Res 1991;559(2):309-14
16. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997;14(1):2-31
17. Welch SP. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J Pharmacol Exp Ther 1993;265 (2):633-40
18. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992;262(1):10-18
19. Welch SP, Thomas C, Patrick GS. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 1995;272(1):310-21
20. Smith FL, Cichewicz D, Martin ZL, et al. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998;60(2):559-66
21. Katona I, Sperlágh B, Sík A, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999; 19(11):4544-58
22. Katona I, Rancz EA, Acsady L, et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 2001;21(23):9506-18
23. Wilson RI, Kunos G, Nicoll RA. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 2001;31(3):453-62
24. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4(11):873-84
25. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 2002;68(4):247-86
26. Reggio PH, Traore H. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem Phys Lipids 2000;108(1-2):15-35
27. Bayewitch M, Avidor-Reiss T, Levy R, et al. The peripheral cannabinoid receptor adenylate cyclase inhibition and G protein coupling. FEBS Lett 1995;375(1-2):143-7
28. Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995;48(3):443-50
29. Takahashi T, Momiyama A. Different types of calcium channels mediate central synaptic transmission. Nature 1993;366(6451):156-8
30. Wheeler DB, Randall A, Tsien RW. Roles of N-type and Q-type Ca2+ channels. in supporting hippocampal synaptic transmission. Science 1994;264(5155):107-11.
31. Mackie K, Lai Y, Westenbroek R, et al. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in ArT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995;15(10):6552-61
32. Pacheco MA, Ward SJ, Childers SR. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res 1993;603(1):102-10
33. Bidaut-Russell M, Devane WA, Howlett AC. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J Neurochem 1990;55(1):21-6
34. Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 1996;16(20):6601-11
35. Whitlow CT, Freedland CS, Porrino LJ. Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat. Psychopharmacology (Berl) 2002;161(2):129-36
36. Rubino T, Patrini G, Parenti M, et al. Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res 1997;44(2):191-7
37. Garcia DE, Brown S, Hille B, et al. Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci 1998;18(8):2834-41
38. Romero J, Garcia-Palomero E, Castro JG, et al. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 1997;46(1-2):100-8
39. Romero J, García L, Fernández-Ruiz JJ, et al. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol. Pharmacol Biochem Behav 1995;51(4):731-7
40. Dill JA, Howlett AC. Regularion of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther 1988;244(3):1157-63
41. Rubino T, Patrini G, Massi P, et al. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998;285(2):813-19
42. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42(4):327-60
43. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006;188:425-44
44. Rodríguez de Fonseca F, Carrera MR, Navarro M, et al. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997;276(5321):2050-4
45. Mailleux P, Vandergaeghen JJ. Dopaminergic regulation of cannabinoid receptor mRNA leels in the rat caudate putamen: an in situ hybridization study. J Neurochem 1993;61:1705-12
46. Mailleux P, Vandergaeghen JJ. Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate putamen. An in situ hybridization study. Neurosci Lett 1993;156:51-3
47. Mailleux P, Vandergaeghen JJ. Glutamatergic regulation of cannabinoid receptor gene expression in the caudate putamen. Eur J Pharmacol 1994;15:193-6
48. Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1996;38(1):21-43
49. Oz M, Zhang L, Morales M, et al. Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes. Synapse 2002;46(3):150-6
50. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995;73(2):907-10
51. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007;23(3):533-43
52. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365(6441):61-5
53. Cabral GA, Dave Pettit DA. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 1998;83(1-2):116-23
54. Howlett AC, Barth F, Bonner TI, et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54(2):161-202
55. Howlett AC. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 1985;27(4):429-36
56. Slipetz DM, O'Neill GP, Fåvreau L, et al. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 1995;48(2):352-61
57. Lemberger L, Rubin A, Wolen R, et al. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 1982;9(Suppl B): 17-23
58. Rubin A, Lemberger L, Warrick P, et al. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther 1977;22(1):85-91
59. Yamamoto I, Watanabe K, Narimatsu S, et al. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol 1995;27(8):741-6
60. Watanabe K, Yamaori S, Funahashi T, et al. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 2007;80(15):1415-19
61. Wilson RS, May EL. Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs. J Med Chem 1975;18(7):700-3
62. Cunningham D, Bradley CJ, Forrest GJ, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 1998;24(4):685-9
63. Hollister LE. Interactions of cannabis with other drugs in man. NIDA Res Monogr 1986;68:110-16
64. Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 2003;304(3):1010-15.
65. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;38:151-78
66. Green K, Kearse EC, McIntyre OL. Interaction between delta 9 tetryhydrocannabinol and indomethacin. Ophthalmic Res 2001:217-20.
67. Ellis E, Moore SF, Willoughby KA. Anandamide and delta 9 THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol 1995;269:1859-64
68. Perez-Reyes M, Burstein SH, White WR, et al. Antagonism of marihuana effects by indomethacin in humans. Life Sci 1991;48:507-15
69. Penetar DM, Kouri EM, Gross MM, et al. Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug Alcohol Depend 2005;79(2):211-23
70. Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323(7303):16-21
71. Cone LA, Greene DS, Helm NA. Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting. Cancer Treat Rev 1982;9(Suppi B):63-70
72. Herman TS, Jones SE, Dean J, et al. Nabilone: a potent anti-emetic cannabinol with minimal euphoria. Biomedicine 1977;27(9-10):331-4
73. Niamatali C, Fallon SD, Egan EL. Nabilone in the management of prochlorperazine resistant cancer chemotherapy induced emesis. Ir Med J 1984;77(9):276-7
74. Einhorn L. Nabilone: an effective anti-emetic agent in patients receiving cancer chemotherapy. Cancer Treat Rev 1982;9(Suppl B):55-61
75. Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev 1982;9(Suppl B):45-8
76. Levitt M. Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev 1982;9(Suppl B):49-53
77. Wada JK, Bogdon DL, Gunnell JC, et al. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev 1982;9(Suppl B):39-44
78. Einhorn LH, Nagy C, Furnas B, et al, Nabilone: an effective anti-emetic in patients receiving cancer chemotherapy. J Clin Pharmacol 1981;21(8-9 Suppl):S64-S69
79. Ahmedzai S, Carlyle DL, Calder IT, et al. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983;48(5):657-63
80. Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 1982;9(Suppl B):25-33
81. Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985;8(4):336-40
82. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1487;79(61):946-52
83. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative anti-emetic for cancer chemotherapy. Arch Dis Child 1986;61(5):502-5
84. Ekert H, Waters KD, Jurk IH, et al. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust 1979;2(12):657-9
85. Sweet DL, Miller NJ, Weddington W, et al. Delta 9-Tetrahydrocannabinol as an anti-emetic for patients receiving cancer chemotherapy. A pilot study. J Clin Pharmacol 1981;21(8-9 Suppl):S70-S75
86. Lucas VS Jr, Laszlo J. Delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 1980;243(12):1241-3
87. Orr LE, McKernan JF, Bloome B. Anti-emetic effect of tetrahydrocannabiol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea. and emesis. Arch Intern Med 1980;140(11):1431-3
88. Sallan SE, Cronin C, Zelen M, et al. Anti-emetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980;302(3):135-8
89. Sallan SE, Zinberg NE, Frei E 3rd. Anti-emetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975;293(16):795-7
90. Priestman TJ, Priestman SG. An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting. Clin Radiol 1984;35(4):265-6
91. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 1991;6(6):352-9
92. Priestman S, Priestman TJ, Canney PA. A double blind randomized cross over comparison of nabilone and metoclopramide in the control of radiation induced nausea. Clin Radiol 1987;38:543-4
93. Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 1986;3(1):39-42
94. Nabilone and high dose metoclopramide anti-emetics for cancer chemotherapy. Drug Ther Bull 1984;22:9-11
95. Cunningham D, Bradley CJ, Forrest GJ, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Ent J Cancer Clin Oncol 1988;24(4):685-9
96. Glare P, Pereira G, Kristjanson LJ, et al. Systematic review of the efficacy of anti-emetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 2004;12(6):432-40
97. Kris MG, Hesketh PJ, Somerfield MR, et al. American society of clinical oncology guideline for anti-emetics in oncology: update 2006. J Clin Oncol 2006;24(18):2932-47
98. Kris MG, Hesketh PJ, Herrstedt J, et al. Concensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005;13(2):85-96
99. Aranda A, Constenla F, Cohes-Funes H, et al. Clinical practice guidelines on anti-emetics in oncology. Expert Rev Anticancer Ther 2005;5:963-72
100. Navari RM, Einhorn LH, Loehter PJ Sr, et al. A Phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007;15(11):1285-91
101. Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003;25(5):485-8
102. Navari RM, Einhorn LH, Passik SD, et al. A Phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005;13(7):529-34
103. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard anti-emetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97(12):3090-8.
104. Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs 2006;11(1):137-51
105. Kalso E. Cannabinoids for pain and nausea. BMJ 2001;323(7303):2-3
106. Campbell FA, Tramèr MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323(7303):13-16
107. Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain - a randomized controlled trial. Wien Klin Wochenschr 2006;118(11-12):327-35
108. Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med 2006;7(1):25-9
109. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006;53(8):769-75
110. Hung O, Lynch ME, Clark AJ. Cannabinoids and pain management. Can J Anaesth 2006;53(8):743-6
111. Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006;253(10):1337-41
112. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362(9395):1517-26
113. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329(7460):253
114. Petro DJ, Ellenberger C Jr. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981;21(8-9 Suppl):S413-S416
115. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14(3):290-6
116. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS., Neurology 2002;58(9):1404-7
117. Notcurt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results firom 34 'N of 1' studies. Anaesthesia 2004;59(5):440-52
118. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10(4):434-41
119. Hagenbach U, Luz S, Ghafoor N, et al. The treatment of spasticity with Delta(9)-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007;45(8):551-62
120. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68(7):515-21
121. Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis-based treatments for neuropathic and multipte sclerosis-related pain. Curr Med Res Opin 2007;23(1):17-24
122. Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13(11):1153-69
123. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118(3):289-305
124. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian pain society. Pain Res Manag 2007; 12(1):13-21